Sorrento Therapeutics Rejects Acquisition Bid Worth Nearly $1 BillionAcquisition Bids, Advisory Committee on Immunization Practices (ACIP), Antibody-Drug Conjugates (ADCs), Business, Cancer, CAR-T Therapy, Clinical Trials, Immuno-oncology, Oncolytic viruses, Pain, R&D, Rejected Acquisition BidsSan Diego-based Sorrento Therapeutics rejected a non-binding acquisition proposal from a private equity firm, saying that the offer “significantly undervalues Sorrento and is not in the best interest of the company’s stockholders.” Read more January 27, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Sorrento-Acquisition-Rejection-BioSpace-1-27-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-01-27 12:37:122020-01-27 13:59:08Sorrento Therapeutics Rejects Acquisition Bid Worth Nearly $1 Billion